Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5812070 | Medical Hypotheses | 2013 | 6 Pages |
Abstract
Ketorolac, a NSAID routinely used during surgery proposed to have anticancer effects, is a promising way to improve postoperative oncological outcome. This effect may be particularly prominent in patients with elevated preoperative inflammatory scores, like the neutrophil:lymphocyte ratio. In this paper, we describe the rationale, the preliminary analyses in our patients, the feasibility and the methodology of a prospective randomized trial called “Ketorolac in Breast Cancer trial” (KBCt) (NCT01806259).
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Developmental Biology
Authors
Patrice Forget, Martine Berlière, Aline van Maanen, Francois P. Duhoux, Jean-Pascal Machiels, Pierre G. Coulie, Gauthier Bouche, Marc De Kock, Ketorolac in Breast Cancer trial (KBCtrial) group Ketorolac in Breast Cancer trial (KBCtrial) group,